

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jenny Louie-Helm et al.

Confirmation No: 1055

Application No: 10/014,750

Group Art Unit: 1615

Filing Date: October 25, 2001

Examiner: Blessing M. Fubara

Title: FORMULATION OF AN ERODIBLE, GASTRIC RETENTIVE ORAL DOSAGE FORM USING IN VITRO DISINTEGRATION TEST DATA

DECLARATION OF INVENTOR JENNY LOUIE-HELM UNDER 37 C.F.R. § 1.132


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I, Jenny Louie-Helm, declare the following:

1. I am the primary inventor of both the instant application and U.S. Patent No. 6,340,475 ("the '475 Patent"). Both the subject application and the '475 Patent are owned by DepoMed, Inc. As an inventor of the subject matter of both the instant application and the '475 Patent, I was at all times working in my capacity as an employee of DepoMed, Inc.

2. As an inventor of the subject matter of the '475 Patent, I was responsible for inventing the use of low the molecular weight polyalkylene oxide polymers in the gastric retention oral dosage forms disclosed in the '475 Patent. Such low molecular weight alkylene oxide polymers also constitutes important subject matter in the instant application. Within the context of the instant application and the '475 Patent, the term low molecular weight polyalkylene oxide polymers refers to those polyalkylene oxide polymers that have a molecular weight of 2,000,000 and below and the term very low molecular weight polyalkylene oxide polymers refers to those polyalkylene oxide polymers that have a molecular weight below 900,000.

Dated: 12/29/03


Jenny Louie-Helm